Atai Life Sciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-33.8	-40.22	-152.39	-167.81	-169.84	-14.14
Depreciation & Amortization	0.8	0.7	0.17	0.05	0.02	0.01
Share-Based Compensation	30.08	32.98	42.38	63.36	67.16	0.06
Other Operating Activities	-82.66	-77.58	5.38	41.15	81.9	6.23
Operating Cash Flow	-85.58	-84.12	-104.47	-63.25	-20.77	-7.85
Capital Expenditures	-0.15	-0.59	-1.02	-1.13	-0.06	-0.02
Acquisitions	-6.96	-5.96	-3	-0.95	0.05	-7.78
Change in Investments	-50.73	-46.75	-82.82	-79.2	-27.92	-1.24
Other Investing Activities	-	0	-	-	-0.34	-
Investing Cash Flow	-57.84	-53.3	-86.85	-81.28	-28.27	-9.03
Share Issuance / Repurchase	-0	0.21	2.29	411.35	82.56	42.68
Debt Issued / Paid	-0.1	-0.1	13.26	4.01	32.5	0
Other Financing Activities	-8.46	-8.46	5.24	-5.5	-2.01	-2.3
Financing Cash Flow	-8.56	-8.36	20.79	409.86	113.05	40.39
Exchange Rate Effect	-0.03	0.19	-1.12	-0.32	3.17	-0.37
Net Cash Flow	-152.02	-145.58	-171.65	265.02	67.18	23.14
Free Cash Flow	-85.73	-84.71	-105.49	-64.37	-20.83	-7.87
Free Cash Flow Margin	-30950.18%	-26977.07%	-45275.11%	-315.93%	-	-
Free Cash Flow Per Share	-0.54	-0.53	-0.68	-0.47	-0.22	-0.09

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).